A new Tufts Center for the Study of Drug Development study shows academic medical center (AMC) and biotech partnerships are increasingly important to basic research and developing new medicines. The study looked at 3000 grants to AMCs from 450 biopharm sponsors through 22 medical schools. Their conclusion is that the nature of these partnerships is continuing to evolve and that they have not yet reached their full potential.
The report looks at 12 primary partnership models of AMC-biopharm collaboration. There is a shift occuring toward more risk- and resource-sharing models rather than the more traditional unrestricted research or fee for service models of the recent past. Rather a range of partnership models is arising from corporate venture funds to pre-competitive research centers to academic drug discovery centers.
The report concludes that in the face of an increasingly challenging R&D environment (often discussd here) and overall global competition, we are likely to see the continued proliferation of AMC-biopharm partnerships.
See full report. Download Tufts AMC-biopharm R&D study
Posted by Bruce Lehr Apr 30th 2012.
My partner and I stumbled over here by a different web
address and thought I might as well check things out.
I like what I see so i am just following you. Look forward to
exploring your web page again.
Posted by: Anthony Richard Clarke Angel Capital Group | 08/17/2012 at 04:59 PM
Here's an example of partnerships announced today from GSK and Yale for new drug class.
http://www.fiercebiotech.com/story/gsk-development-team-tackles-new-drug-class-yale/2012-05-01
Posted by: bigredbruce | 05/01/2012 at 09:37 AM